<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4863">
  <stage>Registered</stage>
  <submitdate>17/09/2014</submitdate>
  <approvaldate>17/09/2014</approvaldate>
  <nctid>NCT02259582</nctid>
  <trial_identification>
    <studytitle>A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer</studytitle>
    <scientifictitle>A 2-Arm Phase 2 Double-Blind Randomized Study of Carboplatin, Pemetrexed Plus Placebo Versus Carboplatin, Pemetrexed Plus Truncated Demcizumab as First-Line Treatment in Subjects With Stage IV Non-Squamous Non-Small Cell Lung Cancer</scientifictitle>
    <utrn />
    <trialacronym>DENALI</trialacronym>
    <secondaryid>M18-007</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Nonsquamous Nonsmall Cell Neoplasm of Lung</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Mesothelioma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Small cell</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Pemetrexed
Treatment: drugs - Carboplatin
Treatment: drugs - demcizumab

Placebo Comparator: Arm 1 Pem, carbo, placebo x 4 cycles - Pemetrexed (500 mg/m2),carboplatin (area under the concentration-time curve of 6 mg/mL x min) once every 21 days X 4 cycles, pemetrexed maintenance and placebo starting at Day 84

Active Comparator: Arm 2 Pem, carbo x 4 cycles, one course of dem - Pemetrexed (500 mg/m2), carboplatin (area under the concentration-time curve of 6 mg/mL x min) x 4 cycles, one course of demcizumab 5mg/kg, maintenance pemetrexed + placebo starting on Day 84

Active Comparator: Arm 3 pem, carbo, dem x 4 cycles, dem retreatment - Pemetrexed (500 mg/m2), carboplatin (area under the concentration-time curve of 6 mg/mL x min) x 4 cycles, maintenance pemetrexed starting on Day 84. 2 courses of demcizumab 5 mg/kg


Treatment: drugs: Pemetrexed


Treatment: drugs: Carboplatin


Treatment: drugs: demcizumab


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Investigator-assessed median progression-free survival (PFS) - Investigator-assessed median progression-free survival as assessed by RECIST v1.1 in Arm 1 to Arm 2 and Arm 1 to Arm 3</outcome>
      <timepoint>Assessed at baseline and every 6 weeks, from randomization until death or disease progression, up to 26.1 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Investigator-assessed RECIST v1.1 response rate - Investigator-assessed RECIST v1.1 response rate in Arm 1 to Arm 2 and Arm 1 to Arm 3</outcome>
      <timepoint>Assessed at baseline and every 6 weeks up to 26.1 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Main 

          1. Signed Informed Consent Form

          2. Histologically or cytologically confirmed Stage IV non-squamous NSCLC

          3. Availability of FFPE tumor tissue, either fresh core-needle-biopsied or archived

          4. Age &gt; or = to 21 years

          5. ECOG performance status of 0 or 1

          6. Disease that is measurable per RECIST v1.1

          7. Adequate organ and marrow function

          8. For women of childbearing potential, agreement to use two effective forms of
             contraception

        Main</inclusivecriteria>
    <inclusiveminage>21</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Histologically or cytologically documented, advanced, mixed non-small cell and small
             cell tumors or mixed adenosquamous carcinomas

          2. NSCLC with known EGFR mutation or anaplastic lymphoma kinase (ALK) gene translocation
             (such as EML4-ALK)

          3. Prior or ongoing therapy (including chemotherapy, antibody therapy, tyrosine kinase
             inhibitors, radiotherapy, immunotherapy, hormonal therapy, or investigational therapy)
             for the treatment of Stage IV non-squamous NSCLC

          4. Evidence of tumor invading major blood vessels, cavitation of one or more pulmonary
             tumor mass(es) ortracheo-esophageal fistula

          5. Brain metastases, leptomeningeal disease, uncontrolled seizure disorder, or active
             neurologic disease

          6. Malignancies other than non-squamous NSCLC successfully treated within 3 years prior
             to randomization (with the exception of certain early-stage cancers)

          7. History of a significant allergic reaction attributed to humanized or human monoclonal
             antibody therapy

          8. Significant intercurrent illness defined as an illness that may result in the
             subject's death prior to their death from non-squamous NSCLC and/or significantly
             limit their ability to comply with the requirements of this study

          9. Recent hemoptysis &gt;2.5 mL or serious bleeding from another site, known bleeding
             disorder or coagulopathy or therapeutic anti-coagulation

         10. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to randomization, or anticipation of need for major surgical procedure during
             the course of the study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>81</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/02/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC,WA</recruitmentstate>
    <hospital>Chris O'Brien Lifehouse - Camperdown</hospital>
    <hospital>The Kinghorn Cancer Centre - Darlinghurst</hospital>
    <hospital>North Coast Cancer Institute Port Macquarie Base Hospital - Port Macquarie</hospital>
    <hospital>Royall Brisbane &amp; Women's Hospital - Herston</hospital>
    <hospital>Icon Cancer Foundation - Milton</hospital>
    <hospital>The Queen Elizabeth Hospital - Woodville South</hospital>
    <hospital>Monash Health, Monash Cancer Centre-Moorabbin - East Bentleigh</hospital>
    <hospital>St. John of God Subiaco Hospital - Subiaco</hospital>
    <postcode>2050 - Camperdown</postcode>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>2444 - Port Macquarie</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode>4064 - Milton</postcode>
    <postcode>5011 - Woodville South</postcode>
    <postcode>3165 - East Bentleigh</postcode>
    <postcode>6008 - Subiaco</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Antwerpen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Charleroi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>La Louviere</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Liege</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lombardia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Piemonte</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pordenone</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Toscana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Avila</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>OncoMed Pharmaceuticals, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Celgene Corporation</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A randomized, double-blind, 3-arm (1:1:1) study in subjects with first-line Stage IV
      non-squamous NSCLC. The purpose is to test the efficacy and safety of demcizumab, when given
      in combination with carboplatin and pemetrexed compared to placebo. The administration of
      carboplatin and pemetrexed is a standard treatment for patients with non-squamous non-small
      cell lung cancer.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02259582</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>